Beam Therapeutics Stock Performance
| BEAM Stock | USD 29.61 2.68 8.30% |
On a scale of 0 to 100, Beam Therapeutics holds a performance score of 5. The firm shows a Beta (market volatility) of 1.92, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Beam Therapeutics will likely underperform. Please check Beam Therapeutics' sortino ratio, semi variance, and the relationship between the standard deviation and value at risk , to make a quick decision on whether Beam Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Beam Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile basic indicators, Beam Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (8.30) | Five Day Return 3.89 | Year To Date Return 9.1 | Ten Year Return 57.92 | All Time Return 57.92 |
1 | Beam Therapeutics Inc. Reports Updated Data From BEACON Phase 12 trial Of Ristoglogene | 12/31/2025 |
2 | Acquisition by Bethany Cavanagh of 5000 shares of Beam Therapeutics at 26.68 subject to Rule 16b-3 | 01/02/2026 |
3 | Disposition of 3034 shares by Bethany Cavanagh of Beam Therapeutics at 30.12 subject to Rule 16b-3 | 01/20/2026 |
4 | Disposition of 6198 shares by Bethany Cavanagh of Beam Therapeutics at 35.0005 subject to Rule 16b-3 | 01/26/2026 |
5 | Is Beam Therapeutics Alpha-1 Update Quietly Reframing the Story of Its Gene-Editing Platform | 02/02/2026 |
6 | IQ EQ FUND MANAGEMENT IRELAND Ltd Buys 188,243 Shares of Beam Therapeutics Inc. BEAM - MarketBeat | 02/06/2026 |
7 | FMR LLCs Strategic Acquisition of Beam Therapeutics Inc. Shares - GuruFocus | 02/11/2026 |
8 | Analyst Bullish on Beam Therapeutics Over Drug Program Trajectory | 02/19/2026 |
9 | Whats Going On With Beam Therapeutics Stock | 02/24/2026 |
| Begin Period Cash Flow | 444.6 M | |
| Total Cashflows From Investing Activities | 185 M |
Beam Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,533 in Beam Therapeutics on November 27, 2025 and sell it today you would earn a total of 429.00 from holding Beam Therapeutics or generate 16.94% return on investment over 90 days. Beam Therapeutics is currently generating 0.4012% in daily expected returns and assumes 5.4678% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than Beam, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Beam Therapeutics Target Price Odds to finish over Current Price
The tendency of Beam Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 29.61 | 90 days | 29.61 | about 26.34 |
Based on a normal probability distribution, the odds of Beam Therapeutics to move above the current price in 90 days from now is about 26.34 (This Beam Therapeutics probability density function shows the probability of Beam Stock to fall within a particular range of prices over 90 days) .
Beam Therapeutics Price Density |
| Price |
Predictive Modules for Beam Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Beam Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Beam Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Beam Therapeutics is not an exception. The market had few large corrections towards the Beam Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Beam Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Beam Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.46 | |
β | Beta against Dow Jones | 1.92 | |
σ | Overall volatility | 2.86 | |
Ir | Information ratio | 0.10 |
Beam Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Beam Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Beam Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Beam Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 63.52 M. Net Loss for the year was (376.74 M) with loss before overhead, payroll, taxes, and interest of (356.09 M). | |
| Beam Therapeutics currently holds about 1.09 B in cash with (347.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.9. | |
| Beam Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from benzinga.com: Whats Going On With Beam Therapeutics Stock |
Beam Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Beam Stock often depends not only on the future outlook of the current and potential Beam Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Beam Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 82.3 M | |
| Cash And Short Term Investments | 850.7 M |
Beam Therapeutics Fundamentals Growth
Beam Stock prices reflect investors' perceptions of the future prospects and financial health of Beam Therapeutics, and Beam Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Beam Stock performance.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (13.08) % | ||||
| Current Valuation | 1.59 B | ||||
| Shares Outstanding | 101.47 M | ||||
| Price To Earning | 37.48 X | ||||
| Price To Book | 2.47 X | ||||
| Price To Sales | 58.83 X | ||||
| Revenue | 63.52 M | ||||
| Gross Profit | (356.09 M) | ||||
| EBITDA | (393.64 M) | ||||
| Net Income | (376.74 M) | ||||
| Cash And Equivalents | 1.09 B | ||||
| Cash Per Share | 15.90 X | ||||
| Total Debt | 161.43 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 4.64 X | ||||
| Book Value Per Share | 9.80 X | ||||
| Cash Flow From Operations | (347.25 M) | ||||
| Earnings Per Share | (4.41) X | ||||
| Market Capitalization | 3.28 B | ||||
| Total Asset | 1.1 B | ||||
| Retained Earnings | (1.57 B) | ||||
| Working Capital | 696.08 M | ||||
| Current Asset | 2.89 B | ||||
| Current Liabilities | 706.6 M | ||||
About Beam Therapeutics Performance
By examining Beam Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Beam Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Beam Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.05) | (0.06) | |
| Return On Capital Employed | (0.28) | (0.26) | |
| Return On Assets | (0.05) | (0.06) | |
| Return On Equity | (0.06) | (0.07) |
Things to note about Beam Therapeutics performance evaluation
Checking the ongoing alerts about Beam Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Beam Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Beam Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 63.52 M. Net Loss for the year was (376.74 M) with loss before overhead, payroll, taxes, and interest of (356.09 M). | |
| Beam Therapeutics currently holds about 1.09 B in cash with (347.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.9. | |
| Beam Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from benzinga.com: Whats Going On With Beam Therapeutics Stock |
- Analyzing Beam Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Beam Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Beam Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Beam Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Beam Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Beam Therapeutics' stock. These opinions can provide insight into Beam Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Will Biotechnology sector continue expanding? Could Beam diversify its offerings? Factors like these will boost the valuation of Beam Therapeutics. Projected growth potential of Beam fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Beam Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.41) | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Beam Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Beam Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Beam Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.